Decrease (-) Restore Default Increase (+)
Bookmark and Share
clear spacerResearch & Clinical Trials

Cardiovascular Clinical Trials

Cardiovascular clinical trials are conducted through Norton Heart Care. If you are interested in participating, please email cvresearch@nortonhealthcare.org.


Acute Coronary Syndrome

Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Sponsor: Sanofi-Aventis

Principal Investigaor: Vipul Panchal, M.D.

Purpose of Study: The purpose of this study is to compare the study drug versus a placebo injection (an inactive solution injection) on the occurrence of future cardiovascular events such as heart attack and stroke, when given in addition to the routine care for lowering cholesterol.


Atrial Fibrillation

Title: The AMPLATZER™ Cardiac Plug (ACP) is a percutaneous transcatheter device intended to prevent thrombus embolization from the left atrial appendage (LAA) in subjects who have nonvalvular atrial fibrillation.

Sponsor: St. Jude Medical Research Center

Principal Investigaor: Abdi Agahtehrani, M.D.

Purpose of Study: The purpose of this research is to evaluate the safety and effectiveness of the AMPLATZER Cardiac Plug (ACP) to prevent clotting complications resulting from atrial fibrillation. 


Title: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II - Orbit-AF II

Sponsor: Janssen Research & Development

Principal Investigaor: C. Gregory Henes, M.D.

Purpose of Study: The purpose of this registry is to better understand how patients diagnosed with A-Fib are cared for by their health-care provider and what happens to them as a result of the care they receive, and in particular, the drug therapy they receive and their associated outcomes.


Chest Pain

Title: PROspective Multicenter Imaging Study for Evaluation of Chest Pain

Sponsor: National Heart, Lung and Blood Institute

Principal Investigaor: William Schmidt, M.D.

Purpose of Study: The purpose of this study is to compare the medical records of different, routinely-performed heart tests, such as exercise treadmill testing, stress echocardiogram, cardiac nuclear imaging, and coronary computed tomograpic angiography (CTA), in identifying heart disease and reducing future heart problems. 


Congestive Heart Failure

Title: PercutAneous Ventricular RestorAtion in Chronic Heart FailUre due to Ischemic HearT DiseasE; A Pivotal Trial to Establish Efficacy and Long-Term Safety of the Parachute Implant System

Sponsor: CardioKinetix, Inc.

Principal Investigaor: Abdi Agahtehrani, M.D.

Purpose of Study: The purpose of this study is to test the safety and effectiveness of the Parachute device for the treatment of heart failure.


Coronary Heart Disease

Title: Global observational study to evaluate the correlation between coronary and carotid atherosclerotic disease and links with clinical outcomes

Sponsor: Montreal Heart Institute Coordinating Center (MHICC)

Principal Investigaor: Vincent DeGeare, M.D.

Purpose of Study: The purpose of this study is to determine the relationship between evaluations made using invasive imaging techniques with a catheter (a long narrow plastic tube which has a very small camera placed at the end) and non invasive (without a catheter, without a needle or injection) ultrasound imaging techniques when looking at plaque build up in heart arteries in patients that participated in the dal-PLAQUE 2 study.


Elevated Risk of Heart Disease Due to Diabetes

Title: Dapagliflozin Effect on CardiovascuLAR Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes

Sponsor: AstraZeneca

Principal Investigaor: Joseph Lash, M.D.

Purpose of Study: The purpose of this study is to see if an investigational drug called dapagliflozin when added to your current treatment for diabetes is effective in reducing cardiovascular events such as heart attack, stroke, and death from heart disease, when compared with placebo (inactive pill having no effect).


Heart Disease and High Blood Sugar

Title: A phase 3B study to evaluate the potential of Aleglitazar to reduce cardiovascular risk in patients with stable cardiovascular disease and glucose abnoralities.

Sponsor: ICON

Principal Investigaor: Joseph Lash, M.D.

Purpose of Study: The purpose of this study is to investigate whether aleglitazar is able to reduce the risk of experiencing a cardiovascular event, such as a heart attack (when blood stops flowing to the heart), or a stroke (when blood stops flowing to the brain) in subjects with stable cardiovascular disease and glucose abnormalities.


High Risk Vascular Disease

Title: Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High Risk for Vascular Outcomes (HRVD) – the ACCELERATE Study

Sponsor: Eli Lilly

Principal Investigaor: Vipul Panchal, M.D.

Purpose of Study: The purpose of this study is to see if the investigational drug, Evacettrapib, is safe and how well it will work to help people who have been diagnosed with “high risk vascular disease.”


Pacemaker Placement

Title: Product Surveillance Registry

Sponsor: Medtronic

Principal Investigaor: Robert Schwartz, M.D.

Purpose of Study: This is a registry study, not an experimental treatment study.  The manufacturer of all or part of your pacemaker device would like to collect information on how their pacemaker is working as long as it is implanted.


Periperal Artery Disease

Title: A randomized, double-blind, parallel group, multicenter phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease

Sponsor: AstraZeneca

Principal Investigaor: Vincent DeGeare, M.D.

Purpose of Study: The purpose of this study is to see if a new medication called ticagrelor given twice daily is effective in preventing the occurrence of heart attack, stroke and/or death due to heart problems in patients who have peripheral arterial disease and if so, how it compares with clopidogrel, given once daily.


 

 

 

 

Medical Care

Cancer
Pregnancy & Prenatal Classes
Weight Loss
Orthopedics
Heart Disease
Neurology
Women's Health
More Medical Care

Locations

Hospitals
Immediate Care
Health Centers
Emergency Room
Doctors Offices
Specialists
Affiliate Hospitals

Patients and Visitors

MyChart
Pay Your Bill
Request an Appointment
Get Healthy
Support Groups
Fitness Groups
Mobile Applications
Clinical Trials
Online Nursery
Classes and Events
Send an eCard
Patient Stories
Places to Stay

About Us

Quality Report 
Careers
Ways to Help
Community Outreach
Contact Us
(502) 629-1234

Connect with us

© 2014 Norton Healthcare
Serving Kentucky and Southern Indiana